Skip to main content
. 2022 Jul 18;10:911551. doi: 10.3389/fpubh.2022.911551

Table 3.

Risk factors affecting SVR in HCV-infected patients with DAAs treatment.

Variables Odds Ratio 95% CI P
Lower Upper
Baseline IP-10 levels (pg/ml) (≤ 450 = 0; >450 = 1) 7.68 1.86 15.68 0.0098
IP-10 decline degree at 4w (>30% = 0; ≤ 30% = 1) 3.42 2.74 13.26 0.0206
Constant 1.266